VTGN — Vistagen Therapeutics Share News
0.000.00%
Last trade - 00:00- $7.97m
- -$23.76m
- $1.27m
VistaGen Q1 revenue rises on licensing agreement expiration
Brief: VistaGen Q1 EPS USD -0.3
Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vistagen Appoints Douglas J. Williamson To Its Board Of Directors
U.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin
Vistagen's anxiety disorder drug misses main goal in late-stage trial, shares plummet (updated)
Vistagen's anxiety disorder drug misses main goal in late-stage trial, shares plummet
U.S. STOCKS ON THE MOVE-Oklo, Fortune Brands, Air Products
NASDAQ RESUMED AT 09:00 AM
Vistagen tumbles as social anxiety drug misses main goal in late-stage trial
Brief: Vistagen Announces Topline And Post-HOC Data From Palisade-4 Phase 3 Public Speaking Challenge Trial Of Fasedienol For The Acute Treatment Of Social Anxiety Disorder
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
Brief: Vistagen Appoints Angel S. Angelov As Chief Medical Officer
Brief: Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Brief: Vistagen Announces Completion Of Last Patient Visit In Palisade-4 Phase 3 Public Speaking Challenge Study Of Fasedienol For Acute Treatment Of Social Anxiety Disorder
U.S. STOCKS ON THE MOVE-Agricultural stocks, Papa John's, Oil companies
U.S. STOCKS ON THE MOVE-Nebius, Scienture, Clearmind
Vistagen cuts 20% of staff to extend cash runway, shares fall